On behalf of the Scientific Program Planning Committee and PDA Europe, we would like to invite you to the Visual Inspection Forum to take place in Berlin / Germany, 21-22 April 2020.
This forum will provide a platform to present and discuss new developments in the field of visual inspection. This year we will have a special focus on the use of automated visual inspection technology to meet this critical process need. Discussion will include both the inspection hardware and software along with the validation strategies necessary to deploy this technology.
We will also cover the emergence of Deep Learning and key concept associated to this step change like data flow and data integrity. We will also address manual inspection which continues to be the reference method for visual inspection. Also, the holistic VI process will be covered with discussions on control strategies such as AQL and defect trending. Key elements of a basic inspection and sampling process along with special considerations for difficult to inspect parenteral (DIP) products such as lyophilized and biopharmaceutical products, and those in special packing types will be covered. The regulatory and compendial requirements that govern the inspection process will also be discussed. On 20 December 2017, the long-awaited revision to Annex 1 of the EU GMP Guidelines was published. While the currently valid Annex 1 only briefly touches on the important topics of container closure integrity control and visual inspection, this revision contains significantly expanded requirements. The new requirements encourage further discussion of the correct understanding and implementation of visual inspection within the pharmaceutical manufacturing supply chain and provide only one of this year‘s hot topics.
We anticipate a strong agenda of knowledgeable experts in this field along with an exhibition of the latest commercial inspection technology and services.
We look forward to seeing you take part in the 2020 Visual Inspection Forum!
John Shabushnig, PhD, Insight Pharma Consulting
Romain Veillon, GSK